Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.03 USD
−101.06 M USD
755.00 K USD
69.26 M
About CELLECTIS
Sector
CEO
André Choulika
Headquarters
Paris
Website
Founded
1999
FIGI
BBG0084L1XN2
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
1h long positionHi my friendt optimal next setup is hear for LONG good RR. Go on x2 or x5 good luck L.
cellectis alcls is going to rise heavilythis is how i see this asset
please refer to my higher time frame analysis for the global view
any comment is welcome
cellectis alcls : begenning of a new cycle
technicaly , it looks like the last phase of correction has ended, i.e the wave C( impulse with 5 waves)
fundamentaly , cellectis is growing big, has very good product, it's an awesome company
notice :
i'm not a financial adviser
i don't have anything to sell ( signal - education- etc..)
I only
Optimal incoming point for last 1 year with profit 500%Optimal incoming point for last 1 year with profit 500% What you mena my friends?
Bullish Looking for rejection off support/resistance line to resume bullish continuation and break through of the double top. Not a likely buy but a good one for the watchlists
CLLS Short IdeaAt significant points of resistance. Look for stock to begin to fall to past support.
$CLLS Breakout trade setup inCellectisEntry level $16 = Target price $19.50 = Stop loss $15
Significant break above 200ma.
Average analysts price target $37 | Buy rating
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.